REAL-WORLD DOSING AND ADHERENCE IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH NABIXIMOLS IN GERMANY

被引：0
|
作者：
Freilich, J. [1 ]
Rodriguez-Rey, Delclaux M. [2 ]
Spelman, T. [3 ]
Yeramaneni, S. [4 ]
Drachenberg, C. [4 ]
机构：
[1] Parexel Int, Stockholm, AB, Sweden
[2] Parexel Int, London, England
[3] Karolinska Inst, Stockholm, Sweden
[4] Jazz Pharmaceut, Palo Alto, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD86
引用
收藏
页码：S376 / S376
页数：1
相关论文
共 50 条
  • [41] Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting
    Seiberl, Michael
    Feige, Julia
    Hilpold, Patrick
    Hitzl, Wolfgang
    Machegger, Lukas
    Buchmann, Arabella
    Khalil, Michael
    Trinka, Eugen
    Harrer, Andrea
    Wipfler, Peter
    Moser, Tobias
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [42] Real-world treatment utilization and effectiveness of onabotulinumtoxinA in multiple sclerosis patients treated for spasticity from the ASPIRE study
    Bandari, D. S.
    Mayadev, A.
    Sakel, M.
    Esquenazi, A.
    Zuzek, A.
    Largent, J.
    Francisco, G. E.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 321 - 322
  • [43] Walking improvements with nabiximols in patients with multiple sclerosis
    G. Coghe
    M. Pau
    F. Corona
    J. Frau
    L. Lorefice
    G. Fenu
    G. Spinicci
    E. Mamusa
    L. Musu
    S. Massole
    R. Massa
    M. G. Marrosu
    E. Cocco
    Journal of Neurology, 2015, 262 : 2472 - 2477
  • [44] Real-world duration of use and dosing frequency of daratumumab in patients with multiple myeloma in the US
    Fonseca, Rafael
    Chinaeke, Eric
    Gupta, Niodita
    Fu, Alex
    Ran, Tao
    Kaila, Shuchita
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S144 - S145
  • [45] Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes
    Hestvik, Anne Lise K.
    Frederiksen, Jette Lautrup
    Nielsen, Helle Hvilsted
    Torkildsen, Oivind
    Eek, Camilla
    Huang-Link, Yumin
    Haghighi, Sara
    Tsai, Jon A.
    Kant, Matthias
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 63
  • [46] Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry
    Papp, Viktoria
    Buron, Mathias Due
    Siersma, Volkert
    Rasmussen, Peter Vestergaard
    Illes, Zsolt
    Kant, Matthias
    Hilt, Claudia
    Mezei, Zsolt
    Roshanisefat, Homayoun
    Sejbaek, Tobias
    Weglewski, Arkadiusz
    van Wingerden, Janneke
    Geertsen, Svend Sparre
    Bramow, Stephan
    Sellebjerg, Finn
    Magyari, Melinda
    PLOS ONE, 2021, 16 (05):
  • [47] Vaccinations in patients with multiple sclerosis: a real-world, single-center, experience
    Sbragia, E.
    Olobardi, D.
    Giovanni, N.
    Lapucci, C.
    Boffa, G.
    Capello, E.
    Cellerino, M.
    Laroni, A.
    Sticchi, L.
    Inglese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 648 - 649
  • [48] Multiple sclerosis patients initiating ofatumumab in the real-world: 6 months data
    Coyle, P.
    Gorritz, M.
    Wade, R.
    Zhou, Z.
    Cao, Y.
    Deshpande, C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 715 - 716
  • [49] Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
    Regner-Nelke, Liesa
    Pawlitzki, Marc
    Willison, Alice
    Rolfes, Leoni
    Oezalp, Sinem-Hilal
    Nelke, Christopher
    Koelsche, Tristan
    Korsen, Melanie
    Grothe, Matthias
    Groppa, Sergiu
    Luessi, Felix
    Engel, Sinah
    Nelles, Gereon
    Bonmann, Eckhard
    Roick, Holger
    Friedrich, Anke
    Knorn, Philipp
    Landefeld, Harald
    Biro, Zoltan
    Ernst, Michael
    Bayas, Antonios
    Menacher, Martina
    Akgun, Katja
    Kleinschnitz, Christoph
    Ruck, Tobias
    Ziemssen, Tjalf
    Pul, Refik
    Meuth, Sven G.
    NEUROLOGICAL RESEARCH AND PRACTICE, 2022, 4 (01):
  • [50] Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis
    Nils-Henning Ness
    Dirk Schriefer
    Rocco Haase
    Benjamin Ettle
    Tjalf Ziemssen
    PharmacoEconomics, 2020, 38 : 883 - 892
12345